13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001616824
Total reported value
$175.7M
$175.7M
32 檔
52.0%
According to the latest 13F quarterly dataset, BML Capital Management, LLC managed an equity portfolio of $175.7M at the end of Q1 2024, spanning 32 distinct U.S. exchange-listed positions.
During Q1 2024, BML Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 17.93% | — | — | |
| 2 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 14.75% | -5.98% | +1.37% | |
| 3 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 12.11% | — | — | |
| 4 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 7.77% | — | — | |
| 5 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 7.68% | +1.74% | +1338.65% | |
| 6 | ✓ | Stock-Other | 7.25% | — | +12.43% | ||
| 7 | CLYM | Climb Bio Inc | Stock-Other | 3.96% | — | +0.63% | |
| 8 | ✓ | Stock-Other | 3.38% | — | — | ||
| 9 | TIL | Instil Bio Inc | Stock-Other | 2.48% | -0.59% | — | |
| 10 | ✓ | Reneo Pharmaceuticals Inc | Stock-Other | 2.38% | — | +65.72% | |
| 11 | CNTB | Connect Biopharma Holdings Limited | Stock-Other | 2.37% | — | -0.00% | |
| 12 | DSGN | Design Therapeutics Inc | Stock-Other | 2.34% | — | -14.57% | |
| 13 | ✓ | Athira Pharma Inc | Stock-Other | 1.63% | — | -38.12% | |
| 14 | ORMP | Oramed Pharmaceuticals Inc | Stock-Other | 1.63% | -4.54% | -33.06% | |
| 15 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 1.46% | -0.18% | — | |
| 16 | ASTC | Astrotech CORP | Stock-Other | 1.30% | — | — | |
| 17 | WING | Wingstop Inc | Stock-Consumer Disc | 1.21% | — | -11.11% | |
| 18 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.94% | — | — | |
| 19 | KNTEUSD | Kinnate Biopharma Inc | Stock-Other | 0.87% | — | +6.54% | |
| 20 | ABIOEUR | Arca Biopharma Inc | Stock-Other | 0.82% | — | — | |
| 21 | TOCAEUR | Forte Biosciences Inc | Stock-Other | 0.81% | — | — | |
| 22 | MIST | Milestone Pharmaceuticals In | Stock-Other | 0.72% | — | +37.03% | |
| 23 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 0.70% | — | — | |
| 24 | LSTA | Lisata Therapeutics Inc | Stock-Other | 0.59% | — | +5.50% | |
| 25 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.58% | — | +0.20% | |
| 26 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.52% | — | — | |
| 27 | NXTCEUR | Nextcure Inc | Stock-Other | 0.45% | — | — | |
| 28 | CALC | Calcimedica Inc | Stock-Other | 0.44% | — | +10.31% | |
| 29 | ANF | Abercrombie & Fitch Co-cl A | Stock-Consumer Disc | 0.31% | — | -88.89% | |
| 30 | QTTB | Q32 Bio Inc | Stock-Other | 0.28% | — | — | |
| 31 | TLIS | Talis Biomedical CORP | Stock-Other | 0.25% | — | — | |
| 32 | ✓ | Stock-Other | 0.10% | — | — |
According to official SEC Form 13F filings, BML Capital Management, LLC reported a total U.S. public equity portfolio value of $175.7M across 32 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SGOV, AVIR, BIL) accounted for 52.0% of total reported equity market value during Q1 2024.
During Q1 2024, BML Capital Management, LLC's top holdings by market value included SGOV (17.9%)、AVIR (14.8%)、BIL (12.1%). The largest single position, SGOV, represented 17.9% of total portfolio value.
In Q1 2024, BML Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.